- Home
- MKZR vs NRSN Comparison
MKZR vs NRSN Comparison
Compare MKZR & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- NRSN
- Stock Information
- Founded
- MKZR 2012
- NRSN 2017
- Country
- MKZR United States
- NRSN Israel
- Employees
- MKZR N/A
- NRSN N/A
- Industry
- MKZR
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- NRSN Health Care
- Exchange
- MKZR Nasdaq
- NRSN Nasdaq
- Market Cap
- MKZR 26.8M
- NRSN 26.0M
- IPO Year
- MKZR N/A
- NRSN 2021
- Fundamental
- Price
- MKZR $1.41
- NRSN $0.91
- Analyst Decision
- MKZR
- NRSN Hold
- Analyst Count
- MKZR 0
- NRSN 1
- Target Price
- MKZR N/A
- NRSN N/A
- AVG Volume (30 Days)
- MKZR 63.6K
- NRSN 172.3K
- Earning Date
- MKZR 01-01-0001
- NRSN 04-08-2025
- Dividend Yield
- MKZR 14.21%
- NRSN N/A
- EPS Growth
- MKZR N/A
- NRSN N/A
- EPS
- MKZR N/A
- NRSN N/A
- Revenue
- MKZR $23,087,751.00
- NRSN N/A
- Revenue This Year
- MKZR N/A
- NRSN N/A
- Revenue Next Year
- MKZR N/A
- NRSN N/A
- P/E Ratio
- MKZR N/A
- NRSN N/A
- Revenue Growth
- MKZR 57.39
- NRSN N/A
- 52 Week Low
- MKZR $1.05
- NRSN $0.51
- 52 Week High
- MKZR $5.50
- NRSN $2.25
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- NRSN 29.02
- Support Level
- MKZR N/A
- NRSN $1.00
- Resistance Level
- MKZR N/A
- NRSN $1.13
- Average True Range (ATR)
- MKZR 0.00
- NRSN 0.08
- MACD
- MKZR 0.00
- NRSN -0.02
- Stochastic Oscillator
- MKZR 0.00
- NRSN 8.23
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.